StockNews.com Initiates Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a research report sent to investors on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Price Performance

Eiger BioPharmaceuticals has a 1 year low of $1.10 and a 1 year high of $43.35. The company’s 50-day moving average is $4.85 and its two-hundred day moving average is $7.03. The firm has a market cap of $2.55 million, a P/E ratio of -0.03 and a beta of 1.83.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.